Table 1.
The immunohistological analysis of GLP-1R revealed that the expression of GLP-1R was associated with positive estrogen and progesterone receptor status, and higher expression of GLP-1R was significantly correlated with better progression-free survival: relationship between GLP-1R expression status and clinicopathological characters
| GLP-1R expression | p | |||
|---|---|---|---|---|
| Number | Low | High | ||
| 154 | 19 | 135 | ||
| Age | ||||
| <50 | 41 | 4 (21.0%) | 37 (27.4%) | NS |
| ≧50 | 113 | 15 (79.0%) | 98 (72.6%) | |
| Histological grade | ||||
| low* | 120 | 11 (57.8%) | 109(90.8%) | 0.0367 |
| high** | 34 | 8 (42.1%) | 26 (76.4%) | |
| FIGO stage | ||||
| Early (stage I-II) | 113 | 14 (73.6%) | 99 (73.4%) | NS |
| Advanced (stage III-IV) | 41 | 5 (26.4%) | 36 (26.6%) | |
| Myometrial invasion | ||||
| < 1/2 | 92 | 11 (57.8%) | 81 (60.0%) | NS |
| ≧1/2 | 62 | 8 (42.2%) | 54 (40.0%) | |
| Lymph node metastasis | ||||
| pN0 | 125 | 14 (73.7%) | 111(82.2%) | NS |
| pN1 | 29 | 5 (26.3%) | 24 (17.8%) | |
| Distant metastasis | ||||
| M0 | 143 | 18 (94.7%) | 125(92.6%) | NS |
| M1 | 11 | 1 (5.3%) | 10 (7.4%) | |
| ER | ||||
| - | 17 | 5 (27.7%) | 12 (9.6%) | 0.0271 |
| + | 125 | 13 (72.3%) | 112(90.4%) | |
| PgR | ||||
| - | 32 | 8 (44.4%) | 24 (17.9%) | 0.0095 |
| + | 120 | 10 (55.6%) | 110(82.1%) | |
| BMI (kg/m2) | ||||
| < 25 | 80 | 14 (77.8%) | 66 (54.1%) | NS |
| ≧ 25 | 60 | 4 (22.2%) | 56 (45.9%) | |
| DM | ||||
| + | 122 | 14 (77.7%) | 108(81.8%) | NS |
| - | 28 | 4 (22.3%) | 24 (18.2%) | |
| Hypertension | ||||
| + | 47 | 6 (12.7%) | 41 (87.3%) | NS |
| - | 103 | 12 (11.6%) | 91 (88.4%) | |
| Dyslipidemia | ||||
| + | 13 | 3 (23.1%) | 10 (76.9%) | NS |
| - | 137 | 15 (11.0%) | 122(89.0%) | |
| PTEN mutation | ||||
| - | 62 | 11 (61.1%) | 51 (38.6%) | NS |
| + | 88 | 7 (38.9%) | 81 (61.4%) | |
| p53 mutation | ||||
| - | 128 | 15 (78.9%) | 113(83.7%) | NS |
| + | 26 | 4 (21.1%) | 22 (16.3%) | |
*histological low grade cancers: G1 and G2 endometrioid cancer
**histological high grade cancers: G3 endometrioid cancer or serous, clear, or undifferentiated carcinoma